Physician profile
Joel D Eichler
NPI 1326033598
$3,437.98
in general payments reported to CMS, 2019-2025
21 companies · $714 in 2025
The $714 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $167 · 2021: $241 · 2022: $387 · 2023: $846 · 2024: $606 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,166.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $892.10 | 2019-2025 | Eylea Hd, Eylea |
| Abbvie INC. | $434.15 | 2022-2025 | |
| Genentech USA, INC. | $378.48 | 2019-2025 | Vabysmo, Lucentis |
| Novartis Pharmaceuticals Corporation | $355.21 | 2019-2020 | |
| Astellas Pharma US INC | $303.22 | 2023-2025 | Izervay |
| Harrow Eye, LLC | $228.31 | 2024-2025 | Triesence, Iheezo |
| Bausch & Lomb Americas INC. | $170.66 | 2022-2025 | Xipere, Visudyne, Miebo |
| Ani Pharmaceuticals, INC. | $86.37 | 2025 | Iluvien, Purified Cortrophin Gel, Yutiq |
| Amgen INC. | $85.71 | 2024-2025 | Tepezza |
| Alimera Sciences, INC. | $67.88 | 2021-2024 | Yutiq, Iluvien |
| Allergan, INC. | $54.64 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $51.88 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $48.06 | 2024-2025 | Syfovre |
| Horizon Therapeutics Plc | $47.78 | 2022-2023 | Tepezza |
| Oyster Point Pharma, INC. | $45.64 | 2022-2023 | Tyrvaya |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $43.34 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $40.80 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $37.62 | 2021 | |
| Aerie Pharmaceuticals, INC. | $27.61 | 2021 | |
| Biogen, INC. | $26.38 | 2023 | |
| Alcon Vision LLC | $12.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Eichler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.